How to Document Chronic Pain Management and Opioid Prescribing

A practical guide for physicians, nurse practitioners, and PAs on documenting chronic pain visits, opioid prescribing decisions, PDMP checks, urine drug screens, risk stratification, treatment agreements, and tapering plans. Covers DEA and state regulatory requirements and how to write notes that demonstrate clinical reasoning for controlled substance prescribing.

Why Chronic Pain Documentation Is Its Own Discipline

Documenting a hypertension follow-up and documenting a chronic pain visit share very little. Both involve a return patient with an ongoing condition. But only one of them requires you to document a controlled substance check with a state prescription database, justify continuing a Schedule II medication at each visit, assess and record a patient's risk for misuse or diversion, and write a note that could someday be reviewed by a DEA investigator, a medical board, a malpractice attorney, or a coroner.

Chronic pain management documentation is high-stakes in a way that most clinical note-writing is not. The notes you write for these patients serve simultaneously as clinical communication, regulatory compliance, liability protection, and evidence of your medical decision-making. Weak documentation in this context does not just create administrative problems. It can put your license at risk.

This guide walks through the core documentation requirements for chronic pain visits, opioid prescribing, and the clinical workflows that surround them. It is written for physicians, nurse practitioners, and physician assistants managing patients with chronic non-cancer pain on long-term opioid therapy.

The Foundation: What Every Chronic Pain Note Must Accomplish

Before getting into specific sections and templates, it is worth being clear about what a chronic pain visit note actually needs to do:

Demonstrate medical necessity for continued opioid therapy at the current dose
Confirm you performed required monitoring steps (PDMP check, urine drug screen, treatment agreement review)
Document the patient's functional status and whether the treatment is achieving its goals
Show your clinical reasoning when you continue, adjust, or taper opioids
Create a defensible record against the three most likely threats: regulatory audit, malpractice claim, and diversion investigation

A note that only records vitals and refills the prescription documents almost nothing useful. A note that captures the patient's function, your monitoring actions, and your reasoning is a clinical record that protects both you and your patient.

Documenting the Prescription Drug Monitoring Program Check

The Prescription Drug Monitoring Program (PDMP) check is now legally required before prescribing opioids in most states, typically at each visit or at minimum at the start of treatment and at specified intervals. But documenting that you checked the PDMP is not enough. Your note needs to capture what you found and what you did with that information.

What to document

Minimum acceptable documentation:

That the PDMP was checked
Date and time of the check (most states require contemporaneous documentation)
Which database was queried (your state's PDMP name)
What the check revealed: no other controlled substance prescribers, or specific findings
Your clinical response to the findings

Example of insufficient documentation: "PDMP checked."

Example of complete documentation: "PDMP (PMP InterConnect, State of Texas) accessed today prior to prescribing. Database shows no controlled substance prescriptions from other providers in the past 90 days. No concerning patterns identified. Prescribing continued as planned."

When the PDMP shows something concerning:

"PDMP accessed today. Database identifies one controlled substance prescription from an outside provider: tramadol 50 mg #30 prescribed by Dr. A. Rodriguez, Family Medicine, on [date]. Patient was not aware this record would be visible. Discussed with patient the importance of coordinating all controlled substance prescribing through a single provider. Patient agreed. Contacted Dr. Rodriguez's office to confirm clinical indication and coordinate care. Documentation of that contact to follow. Adjusting plan based on confirmed tramadol use: [specific adjustments]."

The key principle: document not just the action but the clinical response to what you found.

Risk Stratification Documentation

Risk stratification is the process of assessing a patient's probability of misuse, addiction, or diversion before and during opioid therapy. It is not a one-time intake exercise. It is an ongoing clinical assessment that should be documented at each visit.

Initial risk stratification

At the start of opioid therapy, document your formal risk assessment. Tools like the Opioid Risk Tool (ORT) and the Screener and Opioid Assessment for Patients with Pain (SOAPP-R) generate a scored risk category. Document:

Which tool was used
The patient's score and risk category (low, moderate, high)
Specific risk factors identified
How the risk level influenced your prescribing plan

Example: "Opioid Risk Tool administered at intake. Score: 5 (moderate risk). Risk factors identified: prior history of alcohol use disorder (in remission, last drink approximately 8 years ago per patient report; confirmed in prior records), family history of prescription drug misuse (brother). No personal history of illicit drug use. No history of preadolescent sexual abuse. No current psychiatric disorder. Given moderate risk, initiating opioid therapy with more frequent monitoring: monthly visits, urine drug screening every visit for the first six months, written treatment agreement required."

Ongoing risk reassessment

At each visit, document your reassessment of the patient's behavior and risk status. Even brief documentation is better than none:

"No new risk factors identified at today's visit. Patient denies medication sharing, running out early, or requesting early refills. No behavior changes consistent with emerging misuse. Risk status remains moderate (per ORT at intake). Continuing current monitoring frequency."

When behavior changes, document what changed, what you discussed, and what you decided:

"Patient (Mr. Tavares, 52-year-old male on oxycodone 20 mg q8h for lumbar spinal stenosis) presented today requesting an early refill, stating he lost his medication. This is the second early refill request in four months. Reviewed prescription history in PDMP — no outside prescriptions identified. Spoke with patient directly about this pattern, expressed concern, and reviewed terms of the treatment agreement. Informed patient that lost or stolen medication cannot be replaced under the terms of our agreement. Referred to pharmacy pill counting at next visit. Will consider referral to addiction specialist if this pattern continues."

Treatment Agreement Documentation

The opioid treatment agreement (also called a controlled substance agreement or pain management contract) is a written document that outlines the terms under which you will prescribe opioids. Documenting the agreement properly means more than having a signed copy in the chart.

What your documentation should capture

When the agreement was signed and reviewed
That you reviewed the key terms with the patient (not just handed them a form)
The patient's acknowledgment of the terms
Any updates to the agreement over time
What happened when the agreement was violated, and what you communicated to the patient

Example of agreement review documentation at a follow-up visit:

"Reviewed the controlled substance agreement with Mr. Harrison (patient since 2023, currently on morphine ER 30 mg BID for chronic low back pain secondary to multilevel degenerative disc disease). Agreement last signed and reviewed [date]. Patient verbalized understanding of the following terms: one prescriber for controlled substances, use of designated pharmacy, no sharing of medication, required attendance at follow-up appointments, agreement to urine drug testing. No new concerns identified by patient regarding the agreement terms. Continuing therapy per current plan."

When a patient refuses to sign or violates the agreement

Document this thoroughly. If a patient declines to sign a treatment agreement, document your discussion and what you decided about prescribing. If a patient violates the agreement, document the violation, your conversation with the patient, and your response, including whether you are continuing, tapering, or discontinuing opioid therapy.

Urine Drug Screen Documentation

Urine drug screens (UDS) are a cornerstone of opioid monitoring. Point-of-care screens detect the presence or absence of drug classes. Confirmatory testing provides specific drug identification and quantification. Each type requires different documentation.

Documenting point-of-care UDS results

Document the date, the drugs screened for, and the results. Then document your interpretation and clinical response:

"UDS performed today (point-of-care immunoassay). Results: opiates positive, benzodiazepines negative, THC negative, cocaine negative, amphetamines negative. Expected finding given current oxycodone prescription. No unexpected results. No further confirmatory testing ordered at this time."

Documenting unexpected or concerning UDS results

When the UDS shows something unexpected — a prescribed drug absent, an unprescribed drug present, or a result inconsistent with the clinical picture — this requires more detailed documentation:

"UDS performed today. Results: opiates negative (unexpected, given hydrocodone prescription), benzodiazepines positive (unexpected, no benzodiazepine currently prescribed). Discussed results with patient (Ms. Fernandez, 44-year-old female, on hydrocodone/acetaminophen 10/325 mg TID for fibromyalgia). Patient states she has not been taking the hydrocodone regularly due to nausea, and she took a friend's Valium last week for anxiety. Confirmatory send-out test ordered to verify results (results pending, to be documented upon receipt). Counseled patient on the importance of medication adherence and on the risks of using unprescribed controlled substances. Reminded her of treatment agreement terms. Prescribing decision deferred pending confirmatory testing."

When the confirmatory test returns, document the results and your final decision separately, referencing the initial visit.

Documenting Functional Status and Treatment Goals

The clinical justification for continuing opioid therapy rests partly on demonstrating that the medication is achieving its intended goals. Functional status documentation is how you show that the treatment is providing meaningful benefit, not just managing a prescription.

How to document functional status

Avoid vague improvement language. Instead, document specific functional metrics:

"Patient (Dr. Okafor, 61-year-old physician on long-term opioid therapy for chronic knee pain following bilateral arthroplasty revision) reports that current regimen allows her to work full-time clinic days without requiring additional breakthrough doses. Last week she walked 3 miles without stopping, up from approximately 0.5 miles three months ago. Reports pain 4/10 on average with current regimen vs. 8/10 prior to treatment. Function is meaningfully improved and treatment goals are being met."

When function is not improving, document that clearly and document your response:

"Patient continues to report pain 7/10 on average despite current dose. No improvement in functional goals since last visit three months ago. Work disability status unchanged. Sleep continues to be disrupted. Discussed with patient that current regimen does not appear to be meeting treatment goals and that dose escalation carries increasing risk without evidence of benefit. Referred to pain psychology for evaluation and presented multimodal options (physical therapy, interventional procedures, non-opioid adjuvants). Patient agreed to pursue PT evaluation and psychology consult before any dose change."

Documenting Tapering Plans

When you decide to taper a patient's opioids — whether due to lack of benefit, adverse effects, behavioral concerns, or patient request — your documentation of that decision and plan is particularly important.

What tapering documentation should include

The clinical reason for tapering (specific and supported by documented clinical data)
The proposed taper schedule with specific dose reductions and timeframes
That you discussed the plan with the patient, including the rationale
The patient's response to the discussion
Monitoring plan during the taper
What you will do if withdrawal symptoms become severe

Example:

"Discussed opioid tapering with Ms. Nguyen (57-year-old female, currently on oxycodone ER 40 mg BID and oxycodone IR 10 mg q6h PRN, for CRPS Type I left hand). Rationale for taper: patient reports increasing side effects (constipation requiring laxatives, cognitive slowing that is affecting her work as an accountant, reduced libido), no improvement in functional status over the past year, and expressed desire to reduce her dependence on opioids. Patient is agreeable to a slow taper. Proposed plan: reduce total daily dose by 10% every 2 weeks, starting with reduction of morning ER dose from 40 mg to 36 mg. Will monitor for withdrawal symptoms; patient provided with written information on withdrawal recognition. If significant withdrawal occurs, taper will be slowed. Clonidine 0.1 mg BID available as adjunct if needed. Patient verbalized understanding and agreement with plan. Next visit in 2 weeks."

Documenting Multimodal Treatment

Opioids should rarely be the only treatment in a chronic pain plan. Documenting your multimodal approach strengthens the clinical rationale for continued opioid prescribing by showing that you are not using opioids as a substitute for comprehensive care.

What to document about non-opioid and non-pharmacological treatment

At each visit, briefly document the status of other treatments the patient is engaged with:

"Multimodal pain management plan reviewed. Patient is currently engaged with: weekly physical therapy (ongoing, attending consistently per PT progress notes in chart), cognitive behavioral therapy for chronic pain with Dr. Osei (seen monthly, patient reports skills being helpful), gabapentin 600 mg TID (continued, patient reports approximately 20% additional pain reduction), TENS unit used daily at home. Interventional options discussed: patient declined repeat nerve block at this time due to prior inadequate response. Opioid therapy continues as one component of this multimodal plan."

DEA and State Regulatory Documentation Requirements

Documentation requirements for opioid prescribing vary by state, but several requirements are federal:

Schedule II prescriptions require a written prescription (or electronic equivalent with state approval). Many states now require e-prescribing of controlled substances (EPCS) and mandate that this is documented.
DEA registration numbers cannot be pre-printed on prescriptions in a way that could facilitate forgery. Your documentation should not inadvertently create security vulnerabilities.
Some states require documentation of a physical examination before initiating opioid therapy and at specified intervals.
Several states mandate specific language in the prescriber-patient agreement or require use of a state-issued template.

Know your state's specific requirements. Document that you met them.

Common Documentation Mistakes in Chronic Pain Management

1. Refilling without documenting monitoring. If you checked the PDMP and reviewed the UDS but did not document it, the record does not reflect your clinical diligence.

2. Generic functional status language. "Pain is controlled" and "patient is doing well" are not functional status assessments. Document what the patient can and cannot do.

3. Not documenting the clinical reasoning for dose increases. If you increase an opioid dose, document specifically why: what changed, what you tried before increasing, what you expect the benefit to be, and what would make you reconsider.

4. Missing treatment agreement reviews. Having a signed agreement in the chart does not substitute for periodic review. Document that you reviewed the terms at each visit.

5. Inadequate documentation of concerning behavior. When a patient demonstrates behavior that raises concern, this is a clinical finding. Document what you observed, what you said to the patient, and what you decided.

6. Ignoring functional decline. If your notes consistently document pain improvement but never address whether the patient's function has improved, you are missing a key element of the clinical rationale for continued opioid therapy.

Putting It Together: NotuDocs for Chronic Pain Visit Notes

Chronic pain management visits involve a predictable set of documentation elements that lend themselves well to structured note templates. NotuDocs lets you build a chronic pain template with all required sections built in, so PDMP status, UDS results, risk reassessment, and functional status are captured in every visit without you having to remember each element from scratch. Your clinical reasoning fills the template, not the other way around.

Formal risk stratification tool administered (ORT, SOAPP-R, or equivalent)
Risk score, category, and identified risk factors documented
Informed consent discussion documented (risks, benefits, alternatives)
Treatment agreement signed and reviewed with patient
Functional goals established and documented
Baseline physical examination documented
PDMP checked at initiation

When Adjusting Dose

Clinical rationale for dose change documented
Prior treatments or dose levels tried and their results documented
Expected benefit and timeline specified
Monitoring plan for the new dose documented
Patient agreement and understanding documented

When Tapering

Specific clinical reason for taper documented
Proposed taper schedule with specific reductions and timeframes
Patient response to taper discussion documented
Withdrawal monitoring plan documented
Contingency plan if withdrawal is severe

When Concerning Behavior Is Identified

Specific behavior documented (exact request or observation, not just "concerning")
PDMP findings at the visit documented
Discussion with patient documented, including what was said
Clinical response documented (change in monitoring, referral, dose adjustment, discontinuation)
Follow-up plan documented

Regulatory Compliance

State PDMP check requirements met and documented
EPCS or written prescription requirements met per state law
Physical examination documented per state requirements for controlled substance prescribing
All verbal orders for controlled substances documented and countersigned
Treatment agreement documentation current

Related guides: